Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of AR1001 in early Alzheimer's disease
2023-508306-15-00Phase 3Authorised
- Sponsor
- AriBio
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing AR1001 with Placebo (2 arms). Primary endpoint: Change in CDR-SB from baseline to Week 52. Planned start Jun 2024; status: authorised.
02
Drugs
mirodenafil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2023-508306-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508306-15-00.